By Randall Piper
Anyone who has spent real time in National Accounts has seen the pattern: technology keeps getting better, but the system that’s supposed to adopt it doesn’t speed up. You can bring a tool that clearly solves a problem, saves time, and improves outcomes—and still watch it stall. It’s not apathy; it’s that health system adoption machinery was built for an era when categories changed every few years, not every few months. Innovation is sprinting, the system is jogging, and NAEs are stuck trying to make them meet.
The gap isn’t about intelligence or intent. Supply chain isn’t lazy, and clinicians aren’t clinging to the past. The structure is the problem: annual review cycles, layered committees, and siloed authority. Those processes work for commodity products; they break when a technology touches workflow, data, or cross‑functional operations. So NAEs end up selling two things at once—the product and the organizational permission to even evaluate it.
The real slowdown rarely comes from clinicians; most are open to better tools. What gums up the works is the inconsistent path a new technology must travel before anyone can use it. Within one IDN, the same product can face different processes at different sites. Ownership bounces between supply chain, clinical ops, and IT. Steps shift depending on who you ask, and anything that isn’t urgent gets pushed aside. This friction never shows up in a value analysis packet, but it determines whether a product sees daylight. Systems that adopt well don’t do it with more training—they do it with cleaner, predictable workflows.
Another truth in National Accounts: supply chain leaders have little incentive to stick their necks out. Their world rewards stability—price protection, compliance, standardization, avoiding surprises. When something breaks, they get the call; when something works, the credit goes elsewhere. So a new technology prompts less “Does it work?” and more “What happens to me if it doesn’t?” That’s not stubbornness; it’s rational risk management in a system that punishes failure more than it rewards initiative.
Most IDNs also have a quiet “clinical” category expert who acts as the real gatekeeper. They may not have the biggest title, but internally everyone knows they decide what gets a hearing. If you’re a National Account Executive, you have to find this person—especially with technologies like regenerative wound care or anything that changes clinical workflow. The VAC packet is necessary, but it’s not enough. The gatekeeper has to answer the questions the system runs on: who the clinical champion is, what the product replaces, the net cost delta once utilization and outcomes are considered, and how it fits contractually. If you hand them only the packet, you’re giving them homework. If you bring clear, credible answers—and help them build a case they can defend—you’ve already moved adoption halfway down the road.
The gap is even clearer in the non‑acute world. Much of today’s innovation targets ASCs, home health, SNFs, wound centers, and physician‑owned practices. These sites run lean and move fast; they don’t have staff to “figure it out,” and they can’t navigate hospital‑centric approval pathways. Yet many are governed by the same slow, centralized structures as inpatient care. The result is a bottleneck: the sites that need innovation most are least equipped to clear the adoption pathway. NAEs earn trust here when they can speak to the operational reality of an IDN’s non‑acute footprint, not just the inpatient playbook.
At the center is a simple misalignment: supply chain is measured on stability, not speed, while innovation rewards rapid movement. The scorecard—price protection, contract compliance, SKU reduction, continuity of supply—doesn’t encourage fast adoption and often discourages it. That doesn’t make supply chain “the obstacle.” It makes them rational. NAEs who understand this stop pushing disruption and start aligning: they frame the technology as a way to strengthen the stability supply chain is responsible for protecting.
The NAEs who consistently move technology forward aren’t the ones with the prettiest decks; they bring clarity. They understand the workflow and can explain who touches the product, where it lives, what changes, and what stays the same. They don’t just promise support—they map an implementation path with owners and timelines. They get supply chain, clinical, IT, and operations aligned on the same picture. And they translate value beyond outcomes into operational terms that matter: time saved, steps removed, errors reduced, throughput improved. When NAEs do that, supply chain stops seeing disruption and starts seeing a solution.
This is unfolding as health systems face intense pressure: labor shortages, rising acuity, reimbursement compression, ASC migration, digital transformation demands, and clinician burnout. The need for better tools has never been higher, while the capacity to absorb them has never been lower. That’s the paradox NAEs navigate daily—urgency for innovation rising as adoption bandwidth shrinks.
The adoption gap isn’t going away, but it can be narrowed. The NAEs who will win over the next decade will understand the friction points and speak the language of workflow, not just product. They’ll help IDNs modernize adoption pathways, bridge clinical enthusiasm with operational reality, and become trusted advisors in a system that needs clarity. Innovation will keep accelerating. Supply chain will keep protecting stability. NAEs will stay between the two—and the ones who thrive will turn that tension into value.
Bio: Randy Piper is a healthcare commercial leader with deep experience in IDN strategy, national accounts, GPO ecosystems, and non‑acute performance. He has led enterprise contracting, supplier alignment, and value realization initiatives across major health systems and national partners.
Contact: Email: randall.piper@gmail.com LinkedIn: linkedin.com/in/randallpiper